Gutiérrez A, Sánchez-Payá J, Marco P, Pérez-Mateo M
Department of Internal Medicine, Hospital General Universitario, Universidad Miguel Hernández, Alicante, Spain.
J Clin Gastroenterol. 2001 Apr;32(4):315-8. doi: 10.1097/00004836-200104000-00007.
We assessed the predictive value of fibrinolytic tests for hospital outcome in a prospective study of 84 nonconsecutive patients with acute upper gastrointestinal hemorrhage.
Six readily available parameters of activated fibrinolysis (fibrinogen, D-dimer, tissue plasminogen activator [TPA], plasminogen activator inhibitor type 1 [PAI-1], TPA--PAI-1 complexes, and plasmin-alpha 2-antiplasmin complexes) were tested for association with hospital outcome. Patients were divided into the following three groups: patients who survived and did not require transfusion or surgery, those who survived without surgery but required transfusion, and those who required surgery or died.
Patients with adverse outcome (surgery and/or death) showed significantly higher plasma levels of D-dimer than patients with favorable outcome (p = 0.01). Plasma concentrations of D-dimer >300 ng/mL showed a 20.5% positive predictive value of adverse outcome, with a relative risk of 7.5 (95% CI: 1--57%). Patients who required transfusion showed significantly higher plasma levels of TPA (p = 0.01). A positive correlation between endoscopic bleeding stigmata and D-dimer in the subgroup of patients without liver cirrhosis was found (p = 0.02); however, in the multivariate logistic regression analysis the concentration of D-dimer did not appear as an independent predictor of adverse outcome.
These findings are consistent with the role of increased local fibrinolysis in the digestive tract, particularly of D-dimer, in patients with upper gastrointestinal hemorrhage and adverse outcome. Accordingly, plasma fibrinolytic tests may constitute an appropriate prognostic marker in upper gastrointestinal bleeding.
在一项对84例非连续性急性上消化道出血患者的前瞻性研究中,我们评估了纤溶试验对住院结局的预测价值。
对六项易于获得的活化纤溶参数(纤维蛋白原、D - 二聚体、组织纤溶酶原激活物[TPA]、1型纤溶酶原激活物抑制剂[PAI - 1]、TPA - PAI - 1复合物和纤溶酶 - α2 - 抗纤溶酶复合物)进行检测,以确定其与住院结局的相关性。患者被分为以下三组:存活且无需输血或手术的患者、存活但无需手术但需要输血的患者以及需要手术或死亡的患者。
预后不良(手术和/或死亡)的患者血浆D - 二聚体水平显著高于预后良好的患者(p = 0.01)。血浆D - 二聚体浓度>300 ng/mL时,不良结局的阳性预测值为20.5%,相对风险为7.5(95%可信区间:1 - 57%)。需要输血的患者血浆TPA水平显著更高(p = 0.01)。在无肝硬化的患者亚组中,内镜下出血征象与D -二聚体之间存在正相关(p = 0.02);然而,在多因素逻辑回归分析中,D -二聚体浓度并未表现为不良结局的独立预测因素。
这些发现与上消化道出血且预后不良患者消化道局部纤溶增强,尤其是D -二聚体升高的作用一致。因此,血浆纤溶试验可能是上消化道出血合适的预后标志物。